Collectively, this observation raises the possibility of using Gadd45a as a prognostic biomarker for disease staging and also raises the question of whether elevated levels of Gadd45a observed in initial phases of CML serve to impede disease progression. Here, GADD45A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.